
Sagimet Biosciences Investor Relations Material
Latest events

Study Update
Sagimet Biosciences
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Sagimet Biosciences Inc
Access all reports
Sagimet Biosciences Inc., previously known as 3-V Biosciences, Inc., is a clinical-stage biopharmaceutical company. It focuses on developing innovative therapeutics called fatty acid synthase (FASN) inhibitors. These inhibitors target diseases caused by the overproduction of the fatty acid, palmitate, including non-alcoholic steatohepatitis (NASH), acne, and various forms of cancer. Sagimet Biosciences' expertise in fatty acid synthase allows it to pioneer treatments for these diseases by targeting dysfunctional metabolic pathways. Its lead product candidate, denifanstat, is an oral, once-daily selective FASN inhibitor, currently being evaluated in clinical trials for patients with NASH. The company was incorporated in 2006 and is headquartered in San Mateo, California, USA. Its shares are listed on the Nasdaq.
Key slides for Sagimet Biosciences Inc


Study Update
Sagimet Biosciences Inc


Investor & Analyst Day 2024
Sagimet Biosciences Inc
Latest articles
)
Lowe's Companies: Building a One-Stop Shop for Home Improvement
Lowe's Companies began as a single store in 1921 and has steadily expanded its footprint and offerings, now operating 1,750 stores across the U.S.
7 May 2025
)
Greg Abel: Succeeding Warren Buffett at Berkshire Hathaway
After decades working with Warren Buffett and Charlie Munger, Greg Abel was named Buffett’s successor as he steps down in late 2025.
5 May 2025
)
Intuitive Surgical: Enhancing Surgery with Robotic Precision
Intuitive Surgical has revolutionized surgery with robotics, building its dominant position through decades of innovation, validation, and expansion.
2 May 2025
Ticker symbol
SGMT
Country
🇺🇸 United States